Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.

By Y. Nikiforov, D. Steward, Toni M. Robinson-Smith, B. Haugen, J. Klopper, Zhaowen Zhu, J. Fagin, M. Falciglia, K. Weber, M. Nikiforova. Journal of Clinical Endocrinology and Metabolism, 2009

659 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4b449d3554f3fb2f099f0fd152a123c12a79c642

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Y. Nikiforov

Citations in the corpus

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, positive): “Recently, it has been reported that by molecular testing for thyroid nodules (BRAF, RAS, RET/PTC and PAX8/PPARγ mutations), the presence of any mutation was a strong indicator of cancer because ∼97% of mutation-positive nodules had malignant diagnosis at histology [9, 10] (III, B).”
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “Recent large prospective studies have confirmed the ability of genetic markers (BRAF, Ras, RET=PTC) and protein markers (galectin-3) to improve preoperative diagnostic accuary for patients with indeterminate thyroid nodules (69,73,74).”
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “Testing for a seven-gene panel of mutations (including BRAF, RAS, RET/PTC, with or without PAX8/PPARc) in nodules with cytology suspicious for malignancy is associated with a sensitivity of 50%–68%, specificity of 86%–96%, PPV of 80%–95%, and NPV of 72%–75% in respective single-center studies (162,1”